When it comes to finding relief from minor pain and discomfort, choosing the right lidocaine brand can make a significant difference. Lidocaine, a popular local anesthetic, is used in various formulations to provide effective numbing for a range of conditions. In this article, we will explore some of the top brands known for their high-quality lidocaine products, trusted by consumers and healthcare professionals alike. If you're interested in discovering which brands made it to the list, keep reading to find out more.
Illustration of lidocaine
Best brands of lidocaine in 2025
Endo Pharmaceuticals
Endo Pharmaceuticals is a leading producer of lidocaine products, particularly notable for its contribution to the global lidocaine patches market. The company's 5% lidocaine patch products, such as those offered by Endo Pharmaceutical Inc., are expected to hold a major share of the market due to their widespread availability and effectiveness. Endo's commitment to delivering high-quality generic products, including lidocaine patches, is backed by its extensive experience in the U.S. generic pharmaceutical market, spanning over four decades. The company's innovative approaches and strong distribution channels, including retail and online platforms, further enhance its market presence. For instance, the approval of ZTlido, a lidocaine topical system, by the U.S. Food and Drug Administration in 2018, highlights Endo's innovative capabilities in pain management solutions. Discover more about their products and capabilities.
AstraZeneca
AstraZeneca is a prominent player in the lidocaine market, known for its high-quality pharmaceutical products. The global lidocaine market, which includes AstraZeneca's offerings, is projected to grow significantly, with a CAGR of 8.4% from 2024 to 2032, reaching a market size of USD 3.5 billion by 2032. AstraZeneca's commitment to research and development, as well as its extensive distribution network, contributes to the market's growth. The company's environmental risk assessments ensure that lidocaine is used in a way that presents an insignificant risk to the environment, with a Predicted Environmental Concentration (PEC) / Predicted No Effect Concentration (PNEC) ratio of 6.5 x 10^-2. This underscores AstraZeneca's dedication to both product efficacy and environmental sustainability. More information can be found in their environmental risk assessment report.
Hospira, Inc.
Hospira, Inc., a Pfizer company, is renowned for its high-quality lidocaine hydrochloride products, which are integral in various medical procedures, including dental and surgical anesthesia. The global lidocaine hydrochloride market, valued at USD 512.70 million in 2023, is expected to grow at a CAGR of 5.7% to reach USD 838.60 million by 2032, with North America dominating the market due to increasing surgical procedures and technological advancements. Hospira's products, such as the 1% Lidocaine HCl Injection, USP, are widely used and trusted for their efficacy and safety. However, the company has also taken proactive measures, such as the voluntary recall of mislabeled products in 2021, to ensure patient safety. This commitment to quality and safety underscores Hospira's position as a leading producer of lidocaine hydrochloride.
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. is a leading producer of lidocaine, renowned for its extensive portfolio of generic and innovative medications. In 2023, Teva reported revenues of $15.8 billion, with a significant portion attributed to its generic products, including lidocaine, which contributed to an 8% share of total U.S. generic prescriptions. The company's robust R&D program and global presence, with 43,000 employees, ensure a strong pipeline of high-value medications, including advanced formulations of lidocaine. Teva's commitment to innovation and its unique understanding of local markets have solidified its position as a top generic drug maker. The company's revenues from generic products in international markets and Europe segments have seen notable growth, reflecting the demand for reliable and effective medications like lidocaine. You can read more about their recent performance in the official press release.
Hikma Pharmaceuticals
Hikma Pharmaceuticals is a leading producer of high-quality medicines, including lidocaine, with a strong presence in the global market. The company has expanded its portfolio of injectable medicines significantly, exceeding 150 products in the US, and is recognized as a top-three supplier of generic injectable medicines by volume in the US. Hikma's partnership with AstraZeneca to commercialize the Xylocaine portfolio in emerging regions further solidifies its position in the lidocaine market. Despite challenges in maintaining a consistent supply of lidocaine due to high demand, Hikma continues to grow, with a 6% revenue increase in its injectables segment in 2023. The company's commitment to delivering essential medicines is evident in its global operations across 11 countries.
Sandoz
Sandoz, a division of Novartis, is a leading producer of lidocaine, dominating the market with its extensive range of injectable and topical anesthetic formulations. In 2023, lidocaine, including products from Sandoz, accounted for a market share of 28.7% in the local anesthesia drugs market. Sandoz's lidocaine products are widely used in multimodal pain management strategies to reduce opioid use and side effects. The global lidocaine ointment market, which includes Sandoz's offerings, was valued at US$ 1,275.2 million in 2022 and is expected to grow at a CAGR of 7.7% until 2030. Sandoz's commitment to quality and innovation has made it a trusted name in the pharmaceutical industry. For more information about their lidocaine products, visit Sandoz's official website.
Fresenius Kabi
Fresenius Kabi is a leading global healthcare company renowned for its high-quality lidocaine products, which are essential for various medical procedures, including dental and surgical applications. In response to rising demand, Fresenius Kabi doubled its injectable lidocaine production capacity in October 2022. The company's lidocaine injections are available in various concentrations, such as 1%, 1.5%, and 2%, and are distributed in multiple packaging formats. Despite current shortages due to increased demand and manufacturing delays, Fresenius Kabi remains a trusted provider of lidocaine hydrochloride, contributing significantly to the global market valued at USD 0.773 billion in 2023. With a commitment to improving patient care, Fresenius Kabi employs over 40,000 people worldwide and reported sales of more than EUR8 billion in 2023.
Pfizer
Pfizer is a leading producer of lidocaine, known for its high-quality and reliable products. The company faces current shortages due to manufacturing delays and increased demand, with some products like the 0.5% lidocaine 50 mL flip top vials estimated to be released by December 2026 and the 1% lidocaine 5 mL LifeShield syringes by January 2026. Pfizer's lidocaine hydrochloride injections are extensively metabolized in the liver, with a half-life of 1.5 to 2 hours, and are used in various medical procedures including dental and cosmetic surgeries. The global lidocaine market, in which Pfizer is a key player, was valued at USD 682.22 Million in 2021 and is expected to reach USD 1,137.31 Million by 2030, growing at a CAGR of 5.8%. Pfizer's commitment to product development and strategic alliances helps maintain its strong market position. For more detailed Pfizer lidocaine clinical pharmacology information.
Zydus Pharmaceuticals
Zydus Pharmaceuticals is a leading producer of lidocaine products, notably receiving USFDA approval for Lidocaine and Prilocaine cream 2.5%/2.5%, which is used for topical anesthesia and has annual sales of USD 22.05 million in the US as of October 2024. As the fifth largest unbranded generic corporation in the US, Zydus Pharmaceuticals offers over 500 SKUs and has filed over 129 drug master files and received final USFDA approval on 287 Abbreviated New Drug Applications (ANDAs). The company's commitment to quality and innovation is evident in its state-of-the-art manufacturing facilities, including a new greenfield Oral Solid Dosage (OSD) facility dedicated to US exports. Zydus Lifesciences, the parent company, operates in 55 countries and has more than 30 manufacturing plants worldwide, producing over 28 billion pills annually. With a legacy of over 70 years, Zydus Lifesciences continues to innovate and address unmet healthcare needs globally.
Glenmark Pharmaceuticals
Glenmark Pharmaceuticals is a prominent player in the lidocaine market, known for its robust manufacturing footprint and stringent quality standards. With 14 state-of-the-art manufacturing facilities inspected by regulatory bodies such as the US-FDA and MHRA UK, Glenmark ensures high-quality products. The company has a significant global presence, with operations in the US, India, Europe, and Latin America, and aims to derive 30% of its revenues from specialty and innovative products by 2025. Glenmark's commitment to innovation is evident in its dedicated R&D centers and the development of niche products across therapeutic areas like dermatology, respiratory, and oncology. The company's strong team of over 13,000 employees from 60 nationalities further enhances its capabilities. You can explore more about their formulation products on their website.
Leave a Reply
Your email address will not be published.